Haloperidol

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

Featured evidence outside this drug's tracked markets:MIND-USA (NCT01211522) · Delirium · Phase 3 · missed primary endpoint · Partial signal

Girard et al. (N Engl J Med, 2018; PMID 30346242) report different figures for this outcome: median days alive without delirium or coma of 7.9 with haloperidol, 8.7 with ziprasidone and 8.5 with placebo (P=0.26).

TRECIndia-II (NCT00455234) · Psychotic Disorders · Phase 3 · completed · ungradedHaloquet (NCT01811459) · Delirium · Phase 3 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Schizophrenia
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT00189995 · Beersheva Mental Health Center
— · Schizophrenia
What this study did
NCT00485901 · Eli Lilly and Company
2004-07 – 2005-01 · Schizophrenia
What this study did
Other / comorbidity
NCT07246187 · Mercy Bon Secours Saint Vincent Medical Center
2025-11-06 – 2026-10-01 · Cannabinoid Hyperemesis Syndrome
What this study did
NCT04833023 · Tan Tock Seng Hospital
2022-05-18 – 2025-09-25 · Haloperidol, Advanced Cancer, Hyperactive Delirium, Olanzapine, End-stage Organ Disease
What this study did
NCT05065567 · Corewell Health South
2021-08-30 – 2023-11-20 · Cyclic Vomiting Syndrome
What this study did
NCT03628391 · Erasmus Medical Center
2018-02-22 – 2021-01-23 · Delirium, Critical Illness, Intensive Care Psychosis, Cognitive Impairment, Cognitive Decline
What this study did
NCT02345902 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
2016-01 – 2018-12 · Hypoactive Delirium
What this study did
NCT01211522 · Vanderbilt University Medical Center
2011-12-14 – 2018-07-19 · Delirium, Impaired Cognition, Long Term Psychologic Disorders
What this study did
NCT01811459 · Centre hospitalier de l'Université de Montréal (CHUM)
2013-02 – 2016-09 · Delirium
What this study did
NCT01862302 · McMaster University
2013-08 – 2016-07 · Postoperative Confusion
What this study did
NCT01750541 · Shahid Beheshti University of Medical Sciences
2012-12 – 2013-01 · Psychomotor Agitation
What this study did
NCT00300391 · University of Pittsburgh
2006-03 – 2011-10 · Delirium
What this study did
NCT00250237 · Bronovo Hospital
2005-11 – 2009-02 · Post-Operative Delirium, Hip Fracture
What this study did
NCT00124930 · Alberta Health services
2005-05 – 2008-06 · Nausea, Neoplasms
What this study did
NCT00599287 · UMC Utrecht
2008-02 – 2008-05 · Delirium
What this study did
NCT00455234 · Christian Medical College, Vellore, India
2005-09 – 2006-07 · Psychotic Disorders, Aggression
What this study did
NCT00000179 · National Institute on Aging (NIA)
— · Alzheimer Disease
What this study did
Phase 2/3 (5)
Other / comorbidity
NCT03743649 · M.D. Anderson Cancer Center
2019-07-17 – 2028-12-31 · Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
What this study did
NCT03021486 · M.D. Anderson Cancer Center
2017-06-05 – 2027-06-30 · Advanced Malignant Neoplasm, Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
What this study did
NCT05431595 · M.D. Anderson Cancer Center
2022-07-19 – 2027-02-02 · Delirium, Epileptics, Neuroleptics
What this study did
NCT06168773 · Ain Shams University
2022-11-01 – 2023-11-04 · Delirium in Old Age
What this study did
NCT00340379 · Duke University
2003-04 – 2005-08 · Affective Disorders
What this study did
Phase 2 (8)
Other / comorbidity
NCT06218524 · Southern Medical University, China
2024-12-01 – 2028-07-31 · Glioblastoma Multiforme
What this study did
NCT04750395 · HCA Hospice Care
2021-09-01 – 2024-05 · Delirium, Terminal Illness
What this study did
NCT06428084 · Universitas Padjadjaran
2023-11-01 – 2024-02-28 · Laparoscopic Cholecystectomy
What this study did
NCT02203786 · Centre for Addiction and Mental Health
2009-09 – 2015-09 · Pathological Gambling
What this study did
NCT00126009 · Sanofi
started 2004-05 · Bipolar Disorder
What this study did
NCT00429676 · University of Colorado, Denver
2005-12 – 2007-09 · Delirium, Critical Illness
What this study did
NCT00096863 · Vanderbilt University
2004-12 – 2007-07 · Delirium, Cognition Disorders
What this study did
NCT00000274 · National Institute on Drug Abuse (NIDA)
1997-03 – 1999-05 · Cocaine-Related Disorders, Substance-Related Disorders
What this study did
Phase 1 (10)
Other / comorbidity
NCT07726069 · University of Illinois at Chicago
2026-11 – 2028-01 · Cannabinoid Hyperemesis Syndrome
What this study did
NCT04071639 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-03-12 – 2024-12-31 · Huntington Disease
What this study did
NCT04411953 · Cycle Pharmaceuticals Ltd.
2019-11-15 – 2019-12-19 · Bioequivalence
What this study did
NCT04411940 · Cycle Pharmaceuticals Ltd.
2019-11-15 – 2019-12-18 · Bioequivalence
What this study did
NCT03754062 · King's College London
2017-06-01 – 2019-09-01 · Haloperidol, Placebo, L-DOPA
What this study did
NCT01924468 · National Institute on Drug Abuse (NIDA)
2013-08-14 – 2019-05-14 · Nicotine Dependence
What this study did
NCT01684969 · Eric E. Prommer
2012-03 – 2013-05 · Nausea, Vomiting
What this study did
NCT01259973 · Hospital Clinic of Barcelona
2011-02 – 2011-12 · Pharmacogenetics, Healthy
What this study did
NCT00946491 · Sandoz
1987-04 – 1987-05 · Psychosis
What this study did
Phase 4 (32)
Schizophrenia
NCT02307396 · Technical University of Munich
2015-02-01 – 2016-06-22 · Schizophrenia, Schizophrenia and Disorders With Psychotic Features, Schizoaffective Disorders
What this study did
NCT02199743 · University of Texas Southwestern Medical Center
2013-02 – 2016-06 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01052389 · Mario Negri Institute for Pharmacological Research
2007-07 – 2013-06 · Schizophrenia
What this study did
NCT01161277 · Oslo University Hospital
2010-08 – 2011-06 · Psychosis, Schizophrenia
What this study did
NCT00191555 · Eli Lilly and Company
2003-08 – 2006-05 · Schizophrenia
What this study did
NCT00159081 · Heinrich-Heine University, Duesseldorf
2000-11 – 2005-06 · Schizophrenia
What this study did
NCT00157378 · Ludwig-Maximilians - University of Munich
2000-11 – 2004-12 · Schizophrenia, First-Episode
What this study did
NCT00253110 · Janssen, LP
1996-05 – 1998-09 · Schizophrenia, Schizoaffective Disorder
What this study did
Other / comorbidity
NCT07109245 · Centre for Addiction and Mental Health
2025-12-11 – 2028-12 · Brain Insulin Sensitivity, Healthy Controls, Cognition
What this study did
NCT06395428 · Western Michigan University School of Medicine
2024-07-09 – 2027-04-15 · Back Pain, Chronic Pain
What this study did
NCT03392376 · Zealand University Hospital
2018-06-13 – 2023-07 · Delirium
What this study did
NCT04764344 · Western Michigan University School of Medicine
2021-04-01 – 2023-05-22 · Vomiting, Nausea, Abdominal Pain, Cannabis Use
What this study did
NCT04176055 · University of Calgary
2020-10-13 – 2022-06-01 · Cannabis Hyperemesis Syndrome
What this study did
NCT05246631 · Universitas Indonesia
2020-01-01 – 2020-07-30 · Laparoscopy, Postoperative Nausea and Vomiting
What this study did
NCT03639558 · Joseph Dib
2018-08-28 – 2019-07-07 · Psychiatric Emergency, Aggression, Agitation
What this study did
NCT03056482 · Dr. Marco L.A. Sivilotti
2017-05-21 – 2019-07-07 · Cannabis Use Disorder
What this study did
NCT02433041 · University Hospital, Basel, Switzerland
2013-07 – 2018-12-21 · Postoperative Delirium
What this study did
NCT03199950 · Zuyderland Medisch Centrum
2017-06-23 – 2018-11-23 · Delirium
What this study did
NCT02747511 · Western Michigan University School of Medicine
2015-10 – 2017-10 · Headache, Migraine Disorders
What this study did
NCT02909465 · Tehran University of Medical Sciences
2016-07 – 2017-07 · Ketamine Induced Agitation
What this study did
NCT02972502 · OhioHealth
2014-02 – 2017-04-24 · Headache, Migraine
What this study did
NCT01785290 · Radboud University Medical Center
2013-06 – 2017-03 · Delirium
What this study did
NCT02057549 · The University of Texas Health Science Center, Houston
2012-11 – 2016-11 · Gastroparesis
What this study did
NCT02213900 · Indiana University
2013-09 – 2015-12 · Delirium, Cognitive Impairment, Post-traumatic Stress Disorder, Depression, Anxiety
What this study did
NCT01530308 · Amsterdam UMC, location VUmc
2012-11 – 2015-10 · Delirium
What this study did
NCT02098499 · United States Naval Medical Center, Portsmouth
2013-06-12 – 2015-02-11 · Migraine Headaches, Nausea, Restlessness
What this study did
NCT02103881 · Hennepin Healthcare Research Institute
2014-04 – 2014-06 · Agitation
What this study did
NCT01174290 · Northeastern University
2010-09 – 2014-03 · Subsyndromal Delirium
What this study did
NCT03489551 · Michelle Weckmann
2011-11 – 2013-10 · Stem Cell Transplant Complications, Delirium
What this study did
NCT02143531 · American University of Beirut Medical Center
2008-09 – 2012-08 · Postoperative Nausea and Vomiting
What this study did
NCT00457366 · University of Southern California
2006-05 – 2009-05 · Agitation
What this study did
NCT00009217 · New York State Psychiatric Institute
1999-01 – 2004-12 · Alzheimer's Disease, Psychosis, Agitation
What this study did
Early phase / not applicable (14)
Schizophrenia
NCT00753051 · Khon Kaen University
2008-06 – 2012-05 · Schizophrenia
What this study did
NCT00018850 · US Department of Veterans Affairs
1998-06 – 2003-06 · Schizophrenia
What this study did
Other / comorbidity
NCT07087925 · Rully Riyandika
2025-01-15 – 2025-05-15 · Postoperative Nausea and Vomiting (PONV), Subarachnoid Block, Spinal Anesthesia
What this study did
NCT06014606 · Maastricht University
2021-03-01 – 2023-08-16 · Motivation
What this study did
NCT02625181 · Vanderbilt University
2016-07 – 2017-11-30 · Postoperative Nausea and Vomiting
What this study did
NCT00842608 · Indiana University
2009-02 – 2015-07 · Delirium, Cognitive Impairment
What this study did
NCT01639599 · The Catholic University of Korea
2012-03 – 2013-05 · Gynecological Disease
What this study did
NCT01152697 · University Hospitals Cleveland Medical Center
2010-06 – 2012-08 · Patient Noncompliance
What this study did
NCT00833300 · Richard Hall
2008-06 – 2011-11 · Delirium, Agitation
What this study did
NCT01204255 · Virginia Commonwealth University
2010-11-15 – 2011-05-17 · Healthy
What this study did
NCT01485692 · University of Sao Paulo
2009-02 – 2011-03 · Psychomotor Agitation
What this study did
NCT00625014 · Leiden University Medical Center
2005-03 – 2005-07 · Insulin Resistance, Dyslipidemia
What this study did
NCT00625170 · Leiden University Medical Center
2004-05 – 2004-12 · Insulin Resistance, Dyslipidemia
What this study did
Used as active comparator (39)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (12)
Schizophrenia
NCT00723606 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2008-09 – 2009-07 · Schizophrenia
What this study did
NCT00797277 · National Taiwan University Hospital
2006-07 – 2009-06 · Schizophrenia, Schizoaffective Disorder, Agitation
What this study did
NCT00156065 · Organon and Co
2005-09 – 2007-10 · Schizophrenia
What this study did
NCT00156104 · Organon and Co
2005-07-01 – 2006-09-16 · Schizophrenia
What this study did
Other / comorbidity
NCT06370442 · State University of New York - Upstate Medical University
2024-06-01 – 2025-09-01 · Altered Mental Status
What this study did
NCT05803642 · Qilu Pharmaceutical Co., Ltd.
2023-03-28 – 2024-07-02 · Acute Agitation
What this study did
NCT05690698 · Alexandria University
2023-04-09 – 2023-07-15 · Hyperactive Delirium
What this study did
NCT00954603 · Chiang Mai University
2009-06 – 2012-07 · Delirium
What this study did
NCT01140529 · Thorax-Kärlkliniken
2010-05 – 2012-06 · Postoperative, Delirium, Psychomotor, Confusion
What this study did
NCT00129220 · Eli Lilly and Company
2005-07 – 2009-01 · Bipolar Disorder
What this study did
NCT00097266 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2004-12 – 2007-01 · Bipolar Disorder
What this study did
Phase 2/3 (1)
Schizophrenia
NCT00866645 · Shanghai Mental Health Center
2009-02 – 2010-07 · Agitation
What this study did
Phase 2 (5)
Schizophrenia
NCT00044044 · Sumitomo Pharma America, Inc.
2002-07 – 2003-05 · Schizophrenia
What this study did
Other / comorbidity
NCT04529226 · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
2020-11-26 – 2025-12-30 · Psychosis, Intellectual Disability
What this study did
NCT04715230 · InterveXion Therapeutics, LLC
2021-06-30 – 2022-11-14 · Methamphetamine Intoxication (Disorder)
What this study did
NCT03375671 · David Barbic
2018-05-29 – 2020-03-12 · Violent Aggressive Behavior, Ketamine
What this study did
NCT00505804 · Austin Health
2005-01 – 2008-11 · Delirium, Agitation, Ventilator Weaning, Respiration, Artificial, Intensive Care
What this study did
Phase 1/2 (1)
Schizophrenia
NCT02240173 · Federal Neuro-Psychiatric Hospital, Yaba
2017-06 – 2017-12 · Schizophrenia and Disorders With Psychotic Features
What this study did
Phase 4 (13)
Schizophrenia
NCT03075657 · All India Institute of Medical Sciences, Bhubaneswar
2017-05-01 – 2018-08-31 · Schizophrenia
What this study did
NCT01136772 · New York State Psychiatric Institute
2011-03 – 2016-07 · Schizophrenia, Schizoaffective Disorder
What this study did
NCT01164059 · University of Bremen
2010-02 – 2014-03 · Schizophrenia
What this study did
NCT00419653 · University of Jena
2003-01 – 2007-09 · Schizophrenia
What this study did
NCT00169091 · Harvard Medical School (HMS and HSDM)
1996-03 – 2003-10 · Schizophrenia
What this study did
NCT00007774 · US Department of Veterans Affairs
1998-03 – 2001-06 · Schizoaffective Disorder, Schizophrenia
What this study did
Other / comorbidity
NCT02380118 · The University of Hong Kong
2014-12 – 2019-09 · Acute Agitation, Behavioural Emergency
What this study did
NCT03246620 · The University of Hong Kong
2017-09-01 – 2018-06-01 · Acute Agitation, Behavioural Emergency
What this study did
NCT03110900 · University of Arkansas
2017-09-30 – 2018-04-04 · Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
What this study did
NCT02493192 · Hospital General Universitario Gregorio Marañon
2015-07 – 2016-12 · Parturition, Humanizing Deliver, Labor Pain, Natural Childbirth, Labor Onset, First Labor Stage
What this study did
NCT00767715 · Eli Lilly and Company
2004-10 – 2005-04 · Bipolar Disorder
What this study did
Early phase / not applicable (7)
Schizophrenia
NCT00642369 · Guang Dong Provincial Mental Health Institute
2008-03 – 2009-10 · Schizophrenia
What this study did
NCT00534183 · Central Institute of Psychiatry, Ranchi, India
2006-06 – 2006-12 · Metabolic Syndrome, Diabetes, Obesity
What this study did
NCT01123408 · Nathan Kline Institute for Psychiatric Research
1999-06 – 2004-07 · Schizophrenia
What this study did
Other / comorbidity
NCT06993194 · Benha University
2025-06-15 – 2026-06-15 · Traumatic Brain Injury, Delirium, Agitation
What this study did
NCT01539733 · Amsterdam UMC, location VUmc
2010-03 – 2017-04 · Delirium, Advanced Cancer
What this study did
NCT00615797 · University of Cape Town
2002-05 – 2009-12 · Sydenham Chorea, Post Streptococcal Movement Disorder
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (2)
Other / comorbidity
NCT01949662 · M.D. Anderson Cancer Center
2014-01 – 2028-01-01 · Advanced Cancers
What this study did
NCT00693472 · Merck Sharp & Dohme LLC
2007-08-15 – 2009-01-09 · Akathisia, Drug-Induced, Antipsychotic Agents, Movement Disorders
What this study did
Phase 4 (1)
Other / comorbidity
NCT02343575 · Stanford University
2015-01 – 2018-01 · Hyperactive Delirium, Mixed Delirium
What this study did
Early phase / not applicable (2)
Schizophrenia
NCT03019887 · Juntendo University
2011-04 – 2017-01 · Schizophrenia Relapse
What this study did
NCT00493233 · Centre for Addiction and Mental Health
2006-11 – 2008-12 · Schizophrenia
What this study did

Competitive landscape

This drug's own stage for Schizophrenia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Haloperidol: this drugApprovedSmall moleculeDopamine D2 receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)Reliable signal
NCT03172871: LS mean change from baseline to Week 10 in PANSS Total Score: -33.6 (aripiprazole once-monthly, AOM) vs -34.8 (oral aripiprazole); difference -1.2 (95% CI: -4.1, 1.7), within the pre-defined non-inferiority margin
NCT00706654: Impending relapse by week 26: aripiprazole once-monthly 400 mg 7.12% vs oral aripiprazole 10-30 mg 7.76% (non-inferior); low-dose depot reference arm 21.80%
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT00712686: Mean change in PANSS Total Score from baseline to Week 6: aripiprazole -24.6 vs olanzapine -29.5 (random regression model); treatment difference 4.9 points, 95% CI 2.2-7.6, exceeding the pre-specified 6-point non-inferiority margin -- aripiprazole did not reach non-inferiority (olanzapine was statistically superior). Aripiprazole showed significantly less weight gain at Week 26: +0.13 kg vs +4.30 kg for olanzapine, and fewer patients with significant weight gain (21% vs 40%, p<.05).
Aripiprazole Lauroxil (Aristada Initio)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole Lauroxil (Aristada)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorReliable signal
NCT01469039: The Change From Baseline at Day 85 in Positive and Negative Syndrome Scale (PANSS) Total Score (Data collected from baseline to day 85): Aripiprazole Lauroxil 441 mg -20.9 units on a scale (Standard Error 1.39) | Aripiprazole Lauroxil 882 mg -21.8 units on a scale (Standard Error 1.35) vs Placebo -9.8 units on a scale (Standard Error 1.39)
AsenapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00212771: Mean PANSS total score changes during first year of treatment were - 37.0 asenapine and - 35.3 olanzapine, with further changes of 1.6 asenapine and - 0.8 olanzapine at the extension study endpoint
NCT00212784: Change in total PANSS score (52-week active-controlled trial): asenapine -21.0 vs olanzapine -27.5, difference P<0.0001. missed
Brexpiprazole (Rexulti)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptorPartial signal
NCT03198078: Change from baseline to Week 6 in PANSS total score: brexpiprazole -22.8 (SE 1.5) vs placebo -17.4 (SE 1.6); least-squares mean difference -5.33, 95% CI -9.55 to -1.10, p=0.014
NCT01396421: Change in PANSS total score at Week 6 vs placebo: brexpiprazole 2 mg treatment difference -8.72; 4 mg treatment difference -7.64 (both statistically significant).
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)Reliable signal
NCT01104766: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score. (Baseline to Week 6): Cariprazine 3.0 mg -20.2 Units on a Scale (Standard Error 1.5) | Cariprazine 6.0mg -23 Units on a Scale (Standard Error 1.5) vs Placebo -14.3 Units on a Scale (Standard Error 1.5) | Aripiprazole 10.0 mg -21.2 Units on a Scale (Standard Error 1.4)
NCT01104779: Measurement of Schizophrenia Symptoms: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline to Week 6): Cariprazine (3-6 mg/Day) -22.8 Units on a Scale (Standard Error 1.6) | Cariprazine (6-9 mg/Day) -25.9 Units on a Scale (Standard Error 1.7) vs Placebo -16 Units on a Scale (Standard Error 1.6)
ClozapineApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT03510325: Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed.
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00254202: Change in PANSS total score at day 28: iloperidone 24 mg/day -12.0 (SE 1.03) vs placebo -7.1 (SE 1.48) vs ziprasidone -12.3 (SE 1.44) (CT.gov); iloperidone was superior to placebo on the primary (FANAPT label, Study 2).
Lumateperone (Caplyta)ApprovedSmall moleculeSerotonin 5-HT2A / dopamine D1-D2 receptorPartial signal
NCT04959032: Study 304 (NCT04959032), time to relapse during double-blind phase: HR 0.37 (95% CI 0.22-0.65), 63% relapse-risk reduction vs placebo (p=0.0002); relapse rate 16.4% (18 relapses) lumateperone vs 38.6% (44 relapses) placebo
NCT02469155: Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score (6 weeks): Lumateperone 14 mg (ITI-007 20 mg Tosylate) -15 units on a scale (Standard Error 1.27) | Lumateperone 42 mg (ITI-007 60 mg Tosylate) -14.6 units on a scale (Standard Error 1.23) vs Placebo -15.1 units on a scale (Standard Error 1.21) | Risperidone -20.5 units on a scale (Standard Error 1.33) missed
LurasidoneApprovedSmall moleculeDopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03465787: Change in PANSS total score at week 6 (prespecified primary analysis in the per-protocol set): -26.42±2.02 lurasidone vs -27.33±2.01 quetiapine XR (adjusted mean±SE); difference -0.91 (95% CI -6.35 to 4.53); lower limit above the -8.99 non-inferiority margin, met. The ITT set analysis also showed non-inferiority.
NCT00549718: Change in Total PANSS Score From Baseline to the End of the Double Blind Phase (6 weeks): Lurasidone 40mg -19.2 scores on a scale (95% CI -22.6 to -15.7) | Lurasidone 80mg -23.4 scores on a scale (95% CI -26.9 to -19.9) | Lurasidone 120mg -20.5 scores on a scale (95% CI -24 to -17.1) vs Placebo -17 scores on a scale (95% CI -20.5 to -13.6)
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Weltruza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist)Reliable signal
NCT05693935: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 (Baseline, Week 8): Double-blind: TV-44749 318 mg -21.91 units on a scale (95% CI -25.13 to -18.7) | Double-blind: TV-44749 425 mg -23.44 units on a scale (95% CI -26.52 to -20.36) | Double-blind: TV-44749 531 mg -21.93 units on a scale (95% CI -25.01 to -18.85) vs Double-blind: Placebo -12.17 units on a scale (95% CI -15.34 to -8.99)
Olanzapine (Zyprexa Relprevv)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00088478: 8-week acute study, olanzapine long-acting injection (210 mg/2wk, 300 mg/2wk, 405 mg/4wk) vs placebo: PANSS total score decrease significantly greater for all three LAI regimens vs placebo (p<.001 each).
NCT00320489: Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision) (Baseline up to 104 weeks): Olanzapine Pamoate Depot 644.5 Days (IQR 162 to 740) vs Oral Olanzapine 677.5 Days (IQR 169.5 to 740) missed
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT03510325: Phase 2 symptomatic response (≥40% PANSS reduction) among 111 first-episode-treatment nonresponders re-randomized to second-line therapy: olanzapine 31.7% (13/41) vs amisulpride 44.7% (17/38) vs clozapine 62.5% (20/32); chi-square=6.9, P=.03 missed
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signal
NCT03187769: Percent change from baseline in body weight at Week 12: 4.91% ALKS 3831 vs 6.77% olanzapine; least-squares mean difference −1.87 percentage points (95% CI −3.33 to −0.41; p=0.012).
NCT02634346: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 4 (4 weeks): ALKS 3831 -23.9 units on a scale (Standard Error 1.28) vs Olanzapine -22.8 units on a scale (Standard Error 1.29) vs Placebo -17.5 units on a scale (Standard Error 1.32)
Paliperidone (Invega)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet graded
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 phase 3 result · pivotal pending
Paliperidone Palmitate (Erzofri)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Paliperidone Palmitate (Invega Sustenna)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT02431702: Treatment failure in Part II (9 months): paliperidone palmitate 29.5% vs oral antipsychotics 24.8%, P=0.377; extended 18-month analysis 28.6% vs 44.4%, P=0.080 (DREaM, Schizophr Res 2022). missed
NCT00101634: PANSS total improved vs placebo in all three fixed-dose groups (p=0.02 for 25 and 50 mg equiv., p<0.001 for 100 mg equiv.).
Paliperidone Palmitate (Invega Trinza)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT04072575: Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178
NCT02713282: Symptomatic remission (Andreasen PANSS criteria) at LOCF/Month 12 endpoint: 172/303 patients, 56.8% (95% CI 51.0-62.4)
Perseris
ApprovedUS marketing discontinued
Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT02109562: Mixed Model for Repeated Measures (MMRM) Analysis of Change From Baseline to End of Treatment in the Positive and Negative Syndrome Scale (PANSS) Total Score (Day 1 prior to treatment (Baseline), Days 15, 29, 43 and 57 or early discontinuation): RBP-7000 90 mg -15.367 units on a scale (Standard Error 1.223) | RBP-7000 120 mg -16.456 units on a scale (Standard Error 1.2073) vs Placebo -9.219 units on a scale (Standard Error 1.2162)
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signal
NCT00640601: Percentage of Subjects With Improved Clinical Benefit From Assessment of Clinical Global Impression-Clinical Benefit (CGI-CB) Scale From Baseline to Week 24 or End of Study (Baseline to 24 weeks (or end of study)): Seroquel XR 56.88% (95% CI 50.8 to 62.8)
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00305422: Global cognition improved vs baseline at week 12 on quetiapine (p<0.01) and risperidone (p<0.05).
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00253136: Clinical improvement (>=20% PANSS total score reduction): 47% (Risperdal Consta 25mg) vs 17% (placebo); design (randomized, double-blind, placebo-controlled, 25/50/75mg arms, 12 weeks, Nov 1999-Dec 2000) and this was the pivotal FDA-registration trial for Risperdal Consta, matching NCT00253136's CT.gov record exactly.
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT03503318: Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181
Xanomeline / Trospium Chloride (Cobenfy)ApprovedSmall moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)Reliable signal
NCT04738123: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (From baseline up to Week 5): KarXT -20.6 Score on a scale (Standard Error 1.584) vs Placebo -12.2 Score on a scale (Standard Error 1.552)
NCT04659161: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 5 (Baseline and Week 5): KarXT -21.2 score on a scale (Standard Deviation 1.652) vs Placebo -11.6 score on a scale (Standard Deviation 1.6)
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signal
NCT00403546: Change from baseline in PANSS total score at Week 8, high-dose ziprasidone (320 mg/day) vs standard dose (160 mg/day plus placebo capsules): -8.62 vs -5.48, mixed-model difference -1.37 (95% CI -7.20 to 4.45), p=0.642. No registered primary favoured the high dose; the Simpson-Angus extrapyramidal score was worse on the high dose at Week 2 (difference 1.02, 95% CI 0.08 to 1.95, p=0.033). missed
NCT00159770: Ziprasidone non-inferior to the olanzapine/risperidone/quetiapine group on total PANSS (margin 7 units; P<0.0001).
Cariprazine (Chengdu Kanghong)Phase 3Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine (QLM1016)Phase 3Small moleculeDopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signal
NCT04268303: Change From Baseline in the Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score (Baseline and 2 hours): 120 Micrograms — Baseline: 17.5 score on a scale (Standard Deviation 2.46); 2 Hours: -8.4 score on a scale (Standard Deviation 4.83) | 180 Micrograms — Baseline: 17.6 score on a scale (Standard Deviation 2.69); 2 Hours: -10.4 score on a scale (Standard Deviation 4.34) vs Placebo — Baseline: 17.6 score on a scale (Standard Deviation 2.26); 2 Hours: -4.7 score on a scale (Standard Deviation 4.69)
NCT05658510: Primary endpoint (SERENITY III Part 1, change from baseline in PEC total score at 2 hours), drug vs placebo: p=0.077, not statistically significant.
DireclidinePhase 3Small moleculeMuscarinic M4 receptorPartial signal
NCT05545111: PANSS total score at week 6: 7.5-point placebo-adjusted improvement (p=0.011, effect size 0.61) with 20 mg once daily; 18.2-point improvement from baseline
HS-10380Phase 3Small moleculeDopamine D2/D3 and serotonin 5-HT1A/5-HT2A receptors (multi-target)Partial signalNo reviewed efficacy summary in this indication
LB-102 (methylated Amisulpride)Phase 3Small moleculeDopamine D2/D3 receptor + 5-HT7 receptorReliable signal
NCT06179108: Change From Baseline to Week 4 in the PANSS Total Score (Baseline to Day 28 (4 weeks)): LB-102, 50 mg QD -14.28 score on a scale ± 1.097 vs LB-102, 75 mg QD -13.95 score on a scale ± 1.108 vs LB-102, 100 mg -16.08 score on a scale ± 1.906 vs Placebo Comparator -9.27 score on a scale ± 1.078; p=0.0009 (LB-102, 50 mg QD vs Placebo Comparator), p=0.0022 (LB-102, 75 mg QD vs Placebo Comparator), p=.0017 (LB-102, 100 mg vs Placebo Comparator)
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Reliable signal
NCT00628589: Change in PANSS-EC From Baseline (Baseline and 2 hours): Inhaled Loxapine 5 mg -8.1 units on a scale (Standard Deviation 5.17) | Inhaled Loxapine 10 mg -8.6 units on a scale (Standard Deviation 4.37) vs Inhaled Placebo -5.5 units on a scale (Standard Deviation 4.92)
Olanzapine / Samidorphan (Qilu)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A/5-HT2C receptors (antagonist); mu-opioid receptor (antagonist), Dopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
RoluperidonePhase 3Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
UlotarontPhase 3Small moleculeTAAR1 (trace amine-associated receptor 1)Partial signal
NCT04092686: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): SEP-363856 75mg -16.4 score on a scale (Standard Error 1.49) | SEP-363856 100mg -18.1 score on a scale (Standard Error 1.5) vs Placebo -14.3 score on a scale (Standard Error 1.47) missed
NCT04072354: Change From Baseline in PANSS Total Score at Week 6 (Baseline, Week 6): Adults: SEP-363856 50mg -16.9 score on a scale (Standard Error 1.57) | Adults: SEP-363856 75mg -19.6 score on a scale (Standard Error 1.56) vs Adults: Placebo -19.3 score on a scale (Standard Error 1.55) missed
ANAVEX3-71Phase 2Small moleculeSigma-1 receptor / muscarinic receptor (dual)Partial signal
NCT06245213: ANAVEX3-71-SZ-001 (NCT06245213) achieved its primary endpoint: ANAVEX3-71 was safe and well-tolerated, with no serious TEAEs and no severe TEAEs in either Part A or Part B.
Balipodect (TAK-063)Phase 2Small moleculePhosphodiesterase 10A (PDE10A)Partial signal
NCT02477020: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 (Baseline and Week 6): TAK-063 -19.54 score on a scale (Standard Error 2.412) vs Placebo -14.08 score on a scale (Standard Error 2.474) missed
Betovumeline / Fesoterodine (ML-007C-MA)Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)Partial signal
NCT07038876: PANSS total score change at week 5 vs placebo (mITT): 210/3 mg BID, LS mean difference -4.5 points, Cohen's d 0.37, p=0.015, met. 330/6 mg QD, numerical improvement, not statistically significant (no figure given), missed.
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CPL500036Phase 2Small moleculePDE10AReliable signal
NCT05278156: Change from baseline in PANSS positive subscale at Day 28 (Week 4): 20 mg dose improved 3.7 points (p<0.001, Cohen's d=0.73); 40 mg dose improved 6.3 points (p<0.001, Cohen's d=1.38)
EmraclidinePhase 2Small moleculeMuscarinic M4 receptorPartial signal
NCT05227703: Change From Baseline at Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total Score (Baseline through Week 6): Emraclidine 15mg QD -18.5 score on a scale (95% CI -22 to -15) | Emraclidine 30mg QD -14.2 score on a scale (95% CI -17.5 to -10.8) vs Placebo -16.1 score on a scale (95% CI -19.4 to -12.8) missed
GXV813Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
LY03020Phase 2Small molecule5-HT2C/TAAR1 receptorWeak signalNo reviewed efficacy summary in this indication
NBI-1117570Phase 2Small moleculeMuscarinic M1 and M4 receptors (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tazbentetol (SPG302)Phase 2Small moleculeDendritic spine densitynot yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)Phase 2Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
VV119Phase 2Small moleculeDopamine and serotonin receptors (multi-target antipsychotic)not yet gradedNo reviewed efficacy summary in this indication
Cariprazine Long-Acting Injection (Mapi Pharma)Phase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
JX11502MAPhase 1/2Small moleculeDopamine D3/D2 receptor (partial agonist)Weak signal
NCT05233657: JX11502MA was generally well tolerated at a single dose of 0.25 to 3 mg. The most common treatment-emergent adverse events were somnolence (56.3%), nausea (21.9%), dizziness (18.8%), vomiting (18.8%) and hiccups (18.8%).
AticaprantPhase 1Small moleculeKappa-opioid receptor (inhibitor), Kappa opioid receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Brexpiprazole Long-Acting Injection (Kelun)Phase 1Small moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
HS-10509Phase 1Small molecule—Partial signalNo reviewed efficacy summary in this indication
LY03017Phase 1Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary in this indication
NTX-253Phase 1Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Risperidone (QUAR)Phase 1Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
SEP-380135Phase 1Small molecule—Weak signalNo reviewed efficacy summary in this indication

Large race: only the 60 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Haloperidol to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
Phase 2/3Delirium, Epileptics, NeurolepticsActive not recruiting
Est. primary completion 2027-02-02 · NCT05431595 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Glioblastoma MultiformeNot yet recruiting
Est. primary completion 2027-12-31 · NCT06218524 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 1Cannabinoid Hyperemesis SyndromeNot yet recruiting
Est. primary completion 2028-01 · NCT07726069 · CT.gov ↗
What to watch
August 2028 (1)
Phase 4Brain Insulin Sensitivity, Healthy Controls, CognitionRecruiting
Est. primary completion 2028-08 · NCT07109245 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2/3Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant NeoplasmActive not recruiting
Est. primary completion 2028-12-31 · NCT03743649 · CT.gov ↗
What to watch

See the full readout calendar ↗